Correction to: Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial.
Targeting inflammation in endometriosis: emerging therapeutic options.
Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting up to 10% of reproductive-aged women. Current therapies are predominantly hormone-based and offer symptomatic relief without correcting the immune dysregulation and inflammation …
Feasibility and clinical value of virtual reality based on 3D model in colorectal endometriosis for surgical planning.
Colorectal endometriosis (CRE) is one of the most severe forms of deep pelvic endometriosis with a high risk of major postoperative complications. While pelvic MRI is the gold standard for …
Molecular and Immune Microenvironmental Changes Across Endometrial Lesions: A Comprehensive Immunohistochemical and Clinical Analysis of Progression From Benignity to Carcinoma.
Adenomyosis and endometriosis are estrogen-driven disorders with a recognized potential for malignant transformation, particularly through atypical endometriosis. The molecular and immune mechanisms underlying this progression remain incompletely understood. However, clinical …
The Histamine-Associated Inflammatory Landscape of Endometriosis: Molecular Profiling of HDC, HRH1-HRH4, and Cytokines Across Lesion Subtypes.
Pain in endometriosis involves not only nociceptive but also neuropathic and neurogenic components, reflecting its complex nature. Histamine, a biogenic amine, has emerged as a critical mediator connecting inflammation and …